- Home
- CD vs AUTL Comparison
CD vs AUTL Comparison
Compare CD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CD | AUTL |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.0M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | CD | AUTL |
|---|---|---|
| Price | $5.56 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 128.6K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $949,544.10 | $670.78 |
| Revenue Next Year | $14.69 | $80.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $3.64 | $1.11 |
| 52 Week High | $14.10 | $2.70 |
Technical Indicators
Market Signals| Indicator | CD | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 44.77 |
| Support Level | $4.24 | $1.27 |
| Resistance Level | $6.39 | $1.52 |
| Average True Range (ATR) | 0.80 | 0.12 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 45.34 | 18.27 |
Price Performance
Historical ComparisonAbout CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.